MiMedx Group Inc
NASDAQ:MDXG
MiMedx Group Inc
Operating Income
MiMedx Group Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MiMedx Group Inc
NASDAQ:MDXG
|
Operating Income
$42.3m
|
CAGR 3-Years
41%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is MiMedx Group Inc's Operating Income?
Operating Income
42.3m
USD
Based on the financial report for Dec 31, 2023, MiMedx Group Inc's Operating Income amounts to 42.3m USD.
What is MiMedx Group Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-2%
The average annual Operating Income growth rates for MiMedx Group Inc have been 41% over the past three years , -2% over the past five years .